UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-2142067 (State or other jurisdiction of incorporation or organization) 149 Fifth Avenue Suite 500 New ...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Zack Armen – Head-Investor Relations Jennifer Buell – President and Chief Executive Officer Marc Van Dijk – Chief Scientific Officer Christine Klaskin – Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar – H.C. Wainwright Jack Allen – Baird Matthew Phipps – William Blair Operator Ladies and gentlemen, thank you for standing by. Welcome to the MiNK Therapeutics ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-2142067 (State or other jurisdiction of incorporation or organization) WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40908 MiNK Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or ...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2022 Results Conference Call March 21, 2023 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations at MiNK Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Kalpit Patel - B. Riley Jack Allen - Baird Matt Phipps - William Blair Operator Good morning, and welcome to MiNK Therapeutics' Fourth Quarter and Full Year 2022 Confere ...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2022 Earnings Conference Call November 2, 2022 ET Company Participants Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Jack Allen - Baird Operator Good morning, and welcome to MiNK Therapeutics' Third Quarter 2022 Conference Call and Webcast. All participants will be in a listen-only mode until the question-and-answer session. Please note ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR (Exact Name of Registrant as Specified in its Charter) Delaware 82-2142067 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdic ...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q2 2022 Earnings Conference Call August 9, 2022 11:00 AM ET Company Participants Kimberly Ha - Head of Investor Relations Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Kalpit Patel - B. Riley Securities Jack Allen - Baird Matthew Phipps - William Blair Operator Good day, and welcome to the MiNK Therapeutics Second Quarter 2022 Earnings Conference Call. Please note, today ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdi ...